The key efficacy endpoint was transform from baseline MADRS rating. This quick-expression review observed that, compared to intranasal placebo in addition oral antidepressant, intranasal esketamine in conjunction with an oral antidepressant noticeably enhanced depressive signs or symptoms just after 4 weeks by a indicate difference of four points w… Read More